Evidence map›Paper›PMID 34037709›Full record

ArticleCarcinogenesis2021

Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Shama Virani, Glauco Baiocchi, David Bowtell, Citadel J Cabasag, Kathleen R Cho, Renée T Fortner, Keiichi Fujiwara, Jae-Weon Kim, Martin Köbel, Jean-Emmanuel Kurtz and 10 more

Abstract readConsensus Statement
In one paragraph

Article in Carcinogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  4. What's wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shama ViraniInternational Agency for Research on Cancer (IARC/WHO), Genomic Epidemiology Branch, Lyon, France.ORCID 0000-0002-1163-432X
Glauco BaiocchiDepartment of Gynecology Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
David BowtellWomen's Cancer Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Citadel J CabasagCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Kathleen R ChoDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Tokyo, Japan.
Jae-Weon KimDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Jean-Emmanuel KurtzDepartment of Medical and Surgical Oncology and Hematology, Strasbourg Cancer Institute (ICANS-Europe), Strasbourg, France.
Douglas A LevineGynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Usha MenonMRC CTU at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID 0000-0003-3708-1732
Barbara M NorquistDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.ORCID 0000-0001-5992-7845
Paul D P PharoahDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Anil K SoodDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shelley T TworogerDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-6986-7046
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA.ORCID 0000-0003-1251-0836
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA.ORCID 0000-0002-2324-3393
Paul BrennanInternational Agency for Research on Cancer (IARC/WHO), Genomic Epidemiology Branch, Lyon, France.
Britton TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA.ORCID 0000-0002-1539-6090

Funding

Therapeutic and Diagnostic Factors as Related to Cancer RiskZIACP010128 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$8.1M
Medical Research Council MC_UU_00004/01World Health Organization 001
6 · The paper itself

Abstract

Recently, ovarian cancer research has evolved considerably because of the emerging recognition that rather than a single disease, ovarian carcinomas comprise several different histotypes that vary by etiologic origin, risk factors, molecular profiles, therapeutic approaches and clinical outcome. Despite significant progress in our understanding of the etiologic heterogeneity of ovarian cancer, as well as important clinical advances, it remains the eighth most frequently diagnosed cancer in women worldwide and the most fatal gynecologic cancer. The International Agency for Research on Cancer and the United States National Cancer Institute jointly convened an expert panel on ovarian carcinoma to develop consensus research priorities based on evolving scientific discoveries. Expertise ranged from etiology, prevention, early detection, pathology, model systems, molecular characterization and treatment/clinical management. This report summarizes the current state of knowledge and highlights expert consensus on future directions to continue advancing etiologic, epidemiologic and prognostic research on ovarian carcinoma.

Indexed as

Congresses as TopicFemaleGlobal Burden of DiseaseHumansInternational AgenciesNational Cancer Institute (U.S.)Ovarian NeoplasmsUnited States

Identifiers

PMID34037709
PMCPMC8427725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.